Welcome to our dedicated page for Adagene SEC filings (Ticker: ADAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagene Inc. (Nasdaq: ADAG) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, and this page aggregates those SEC filings for detailed review. The company submits Form 6-K current reports that incorporate press releases, financial statements, and transaction disclosures by reference into its registration statements on Form F-3 and Form S-8. These filings provide insight into Adagene’s clinical-stage operations, financing arrangements, collaborations, and risk disclosures related to its antibody-based cancer immunotherapy programs.
Within Adagene’s filings, investors can find information on its Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody technologies, and on its lead clinical program ADG126 (muzastotug), a masked, anti-CTLA-4 SAFEbody in development for metastatic microsatellite-stable colorectal cancer in combination with anti-PD-1 therapy. Form 6-K reports have included financial results for specified periods, descriptions of research and development and administrative expenses, and commentary on how the company prioritizes development of ADG126. They also describe strategic transactions such as Sanofi’s agreement to make a strategic investment through Series A non-voting convertible preferred shares and the associated terms of conversion, voting, dividends, and liquidation preferences.
Adagene’s SEC submissions further document collaboration and license agreements with partners including Exelixis, Sanofi, and other counterparties, as well as borrowings from various banks and related-party transactions. These disclosures outline milestone and royalty structures, option exercises for SAFEbody discovery programs, and the use of proceeds from financing activities to support clinical development of muzastotug and other research programs.
On Stock Titan, users can access Adagene’s SEC filings as they are furnished to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain key elements of Form 6-K reports, highlight material terms in agreements, and surface information on clinical development plans, capital structure, and risk factors, allowing readers to navigate lengthy regulatory filings more efficiently.
Adagene Inc. executive director of human resources Zhou Ling filed an initial Form 3 reporting existing equity holdings in the company. The filing shows direct ownership of 2,969 ordinary shares, 9,375 restricted stock units and multiple nonqualified stock options over ordinary shares.
The RSUs were granted under Adagene’s 2021 Performance Incentive Plan, with 3,125 units scheduled to vest on each of 7/23/2026, 7/23/2027 and 7/23/2028. Option positions include fully vested grants over 25,000, 3,125 and 1,250 shares, plus additional time-based options ranging from 20,000 to 35,000 underlying shares with exercise prices between 1.0400 and 5.6000 per share and expirations from 2030 through 2036.
Adagene Inc. director Zhu Li filed an initial statement of beneficial ownership, detailing nonqualified stock options over the company’s ordinary shares. The filing shows options covering 20,000 shares at an exercise price of $1.1500 per share that are fully vested and exercisable under the Adagene Inc. 2021 Performance Incentive Plan.
It also lists options over 25,000 shares at $1.5500 per share granted on December 24, 2024, which vest 25% on each of the first four anniversaries of the grant date; 6,250 of these shares are vested and exercisable. A further 25,000-share option at $2.0320 per share was granted on February 5, 2026, becoming exercisable as to 25% of the shares on each of the first four anniversaries of that grant.
Adagene Inc. executive director of finance Gu Chunfang filed an initial Form 3 showing existing equity interests in the company. The filing lists direct holdings of stock options over multiple blocks of Ordinary Shares, with exercise prices ranging from 1.04 to 5.60 per share and expirations between 2029 and 2036. Gu also holds 7,045 Ordinary Shares directly and 23,438 Restricted Stock Units under the Adagene Inc. 2021 Performance Incentive Plan. According to the vesting schedule, 7,813 RSUs are scheduled to vest on each of 7/23/2026, 7/23/2027, and 7/23/2028, while several option grants are already fully vested and exercisable.
Adagene Inc. director Andy Yiu Leung Cheung filed an initial ownership report showing he holds several nonqualified stock options over the company’s ordinary shares. These options cover 20,000 shares at an exercise price of $11.2000 per share expiring on June 18, 2031, 25,000 shares at $1.5500 per share expiring on December 24, 2034, and 25,000 shares at $2.0320 per share expiring on February 5, 2036. The filing notes that 20,000 option shares are fully vested and exercisable, while 6,250 shares from the 25,000-share grant dated December 24, 2024 are currently vested, with the remainder of that grant and the latest 25,000-share grant scheduled to vest in 25% annual installments.
Adagene Inc. executive Zhao Qinghai, the Chief Manufacturing Officer, filed an initial statement of beneficial ownership showing a mix of ordinary shares, stock options, and restricted stock units in the company.
The filing lists several incentive and performance-based stock options over ordinary shares with exercise prices ranging from $1.04 to $5.60 per share and expiration dates between 2030 and 2036. Footnotes explain that some option grants are fully vested and exercisable, while others vest over four years or in two large tranches in 2025 and 2026. Zhao also holds 130,214 ordinary shares directly and 37,500 restricted stock units granted under Adagene’s 2021 Performance Incentive Plan, with 12,500 RSUs scheduled to vest on each of July 23, 2026, July 23, 2027, and July 23, 2028.
Adagene Inc. director Do Cuong V has reported existing stock option holdings in a Form 3. The filing lists an incentive stock option covering 40,000 ordinary shares at an exercise price of $0.8000 per share, expiring on November 28, 2032. These 40,000 time-based options were granted on November 28, 2022 and are fully vested and exercisable. It also lists a nonqualified stock option for up to 50,000 ordinary shares at $1.0700 per share, expiring on October 26, 2033, which will become exercisable only upon achievement of specified performance milestones.
Adagene Inc. director Ulf Grawunder filed an initial ownership report showing direct holdings of ordinary shares and stock options. He directly owns 25,000 Ordinary Shares. He also holds nonqualified stock options over 40,000 ADAG Ordinary Shares with a $2.2600 exercise price expiring on April 8, 2034, and options over 25,000 ADAG Ordinary Shares with a $2.0320 exercise price expiring on February 5, 2036. Footnotes state the 40,000-share option was granted on April 8, 2024 under the 2021 Performance Incentive Plan and vests 50% on each of the first two anniversaries, so 20,000 shares are currently vested and exercisable. The 25,000-share option was granted on February 5, 2026 and vests 25% on each of the first four anniversaries.
General Atlantic-affiliated funds report that they no longer beneficially own any Adagene Inc. shares. As of December 31, 2025, the group reports beneficial ownership of 0 American Depositary Shares (ADSs) and 0 underlying ordinary shares, equal to 0% of the class.
The filing notes that each ADS represents one and one quarter ordinary shares. Percentage calculations reference 58,914,087 ordinary shares outstanding as of June 30, 2025, as reflected in an Adagene prospectus filed with the SEC on January 9, 2026.
Adagene Inc. shareholder Vincent C. Smith and related entities filed an amended Schedule 13G reporting significant ownership of the company’s Ordinary Shares. Mr. Smith may be deemed to beneficially own 5,095,351 Ordinary Shares, or 8.7% of the class, including shares held directly and through affiliated entities.
The Vincent C. Smith, Jr. 2025 Annuity Trust beneficially owns 3,608,019 Ordinary Shares, representing 6.1% of the class, while VCS Master Holdings GP holds 185,701 Ordinary Shares, or 1.0%. These percentages are based on 58,914,087 Ordinary Shares outstanding as of June 30, 2025. The filing states the securities were not acquired to change or influence control of Adagene.
Adagene Inc. filed a 6-K highlighting its cash position and development plans for 2026. The company reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, which it anticipates will fund operations until late 2027. This figure is preliminary, unaudited, subject to finalization, and is not a substitute for audited US GAAP financial statements.
Adagene’s lead program, muzastotug (ADG126), is a masked anti-CTLA-4 antibody (SAFEbody) with FDA Fast Track designation, being studied in Phase 1b/2 and Phase 2 trials in combination with anti-PD-1 therapy, particularly in microsatellite stable metastatic colorectal cancer. A data update from the ongoing Phase 1b/2 study of muzastotug plus pembrolizumab in third-line and later MSS colorectal cancer patients remains on track for Q1 2026. The company emphasizes its platform technologies (SAFEbody, NEObody, POWERbody) aimed at improving the safety and precision of antibody-based cancer immunotherapies.